Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …

Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an
unmet need for treatments that provide rapid and high levels of skin clearance and itch …

We previously reported durable responses and manageable safety of ibrutinib from a 3-year
follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (…

Background Systemic therapies are typically combined with topical corticosteroids for the
management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (…

Background The TP53 gene, encoding tumour suppressor protein p53, is located on the
short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic …

Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and …

Background The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This
study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients …

Importance Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated
upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-…

Background Primary (week 16) results from the ongoing phase 3, double-blind AD Up study
(NCT03568318) demonstrate a positive benefit–risk profile for upadacitinib + topical …

Background: Ibrutinib (ibr), a first-in-class, once-daily Bruton’s tyrosine kinase inhibitor, is
approved by the US FDA for treatment of patients (pts) with chronic lymphocytic leukemia/small …